CliffBio
small molecule

DUOPA

CARBIDOPA; LEVODOPA

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameDUOPA
Active ingredientCARBIDOPA; LEVODOPA
Strength4.63MG/ML;20MG/ML
Dosage formSUSPENSION
RouteENTERAL
ModalitySmall molecule
FDA approvalJanuary 2015
Marketing statusRX

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DUOPA patent cliff — loss of exclusivity — | CliffBio